XML 75 R57.htm IDEA: XBRL DOCUMENT v3.19.1
Intangible Assets (Narrative) (Details) - USD ($)
shares in Thousands
1 Months Ended 12 Months Ended
Oct. 29, 2013
Nov. 30, 2018
Nov. 30, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items]              
Other revenue, potential upfront payment related to product sales       $ 4,600,000      
Additions to intangible assets       3,819,486 $ 1,213,110 $ 2,000,226  
Payments to acquire businesses       20,000,000 0 0  
Goodwill       784,000 0    
Amortization of intangible assets       2,769,466 2,436,222 $ 2,194,039  
Product and License Rights              
Acquired Finite-Lived Intangible Assets [Line Items]              
Intangible assets, gross       36,573,941 21,879,981    
Patents              
Acquired Finite-Lived Intangible Assets [Line Items]              
Intangible assets, gross       9,428,266 9,177,647    
Additions to intangible assets       400,000 400,000    
Vaprisol | Product and License Rights              
Acquired Finite-Lived Intangible Assets [Line Items]              
Intangible assets, gross             $ 3,000,000.0
Pernix Therapeutics | Collaborative Arrangement, Amended International Agreement              
Acquired Finite-Lived Intangible Assets [Line Items]              
Other revenue, potential upfront payment related to product sales $ 4,000,000.0     2,300,000      
Methotrexate              
Acquired Finite-Lived Intangible Assets [Line Items]              
Payments to acquire businesses     $ 100,000        
Stock issued during period, acquisitions       1,100,000 $ 1,300,000    
VIBATIV              
Acquired Finite-Lived Intangible Assets [Line Items]              
Payments to acquire businesses   $ 20,000,000.0   $ 20,000,000      
Intellectual property amortizable intangible assets   11,700,000          
Goodwill   $ 784,000          
Restricted Stock | Methotrexate              
Acquired Finite-Lived Intangible Assets [Line Items]              
Stock issued during period, acquisitions (in shares)     180